Pangu
Contact
Clinical Trials
Patients

Skip to content

Company
Our Science
R&D
Patients
Careers
- Working at aTyr
- Career Opportunities
Investors and Media

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

Efzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor

Keystone Symposia: Myeloid Cell Diversity, 2024

« Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

Efzofitimod is an Immunomodulator of Myeloid Cell Function and Novel Therapeutic Candidate for Interstitial Lung Diseases »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

By continuing to browse this site, you agree to our use of cookies.

MENU

Company
Our Science
R&D
Patients
Careers
- Career Opportunities
- Working at aTyr
Investors and Media
Privacy Policy